HUMA supply chain intelligence for Humacyte, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Humacyte, Inc. (HUMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AVENUE-VENTURE-OPPORTUNITIES-FUND-II-L-P | AVENUE-VENTURE-OPPORTUNITIES-FUND-II-L-P | 92% | The cash payment was funded with proceeds from a senior secured term loan facility with Avenue Venture Opportunities Fund II, L.P. |
| BARCLAYS-CAPITAL-INC | BARCLAYS-CAPITAL-INC | 92% | On June 10, 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division o… |
| BTIG-LLC | BTIG-LLC | 92% | On June 10, 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division o… |
| CONFLUENT-MEDICAL-TECHNOLOGIES-INC | CONFLUENT-MEDICAL-TECHNOLOGIES-INC | 92% | Confluent Medical Technologies, Inc. ("Confluent") is the current single source supplier of the polymer mesh we use |
| SERACARE | SERACARE | 92% | SeraCare, which was subsequently acquired by LGC Clinical Diagnostics, Inc. ("SeraCare"), is the current single source supplier of human plasma used in our manufacturing process |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | The Company has agreed to pay TD Cowen a commission of up to 3.0% of the gross proceeds from the sales of Shares pursuant to the Agreement. |
| TITAN-PARTNERS-GROUP-LLC | TITAN-PARTNERS-GROUP-LLC | 92% | On June 10, 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division o… |
| TITAN-PARTNERS-GROUP-LLC-A-DIVISION-OF-AMERICAN- | TITAN-PARTNERS-GROUP-LLC-A-DIVISION-OF-AMERICAN- | 92% | On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement … |
| LINCOLN-PARK | LINCOLN-PARK | 90% | On September 24, 2024, we entered into the Common Stock Purchase Agreement with Lincoln Park for an equity line financing |
| TMO | Thermo Fisher Scientific Inc. | 90% | We source bioprocess solutions, including culture media and decellularization buffers, from a division of Thermo Fisher Scientific |
| TMO | Thermo Fisher Scientific Inc. | 90% | Reciprocal relationship from TMO graph: Reciprocal relationship from HUMA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from HUMA graph: Reciprocal relationship from TMO grap… |
| FMS | Fresenius Medical Care AG | 72% | Reciprocal relationship from FMS graph: Reciprocal relationship from HUMA graph: Reciprocal relationship from FMS graph: Reciprocal relationship from HUMA graph: Reciprocal relationship from FMS grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FRESENIUS-MEDICAL-CARE-HOLDINGS-INC | FRESENIUS-MEDICAL-CARE-HOLDINGS-INC | 92% | Under the Agreement, Humacyte granted to Fresenius rights to develop and commercialize the Company’s 6 millimeter acellular tissue engineered vessel-tyod (the “Distribution Product”) outside of the U.S. |
| KSA-BASED-ENTITY | KSA-BASED-ENTITY | 90% | The evaluation of Symvess is planned to be conducted in parallel with ongoing negotiations with a KSA-based entity for establishment of a joint venture and license to commercialize Symvess within the… |
| ANNUAL-REPORT-SMALLER-REPORTING-COMPANY | ANNUAL-REPORT-SMALLER-REPORTING-COMPANY | 62% | Item 1 of this Quarterly Report on Form 10-Q have been prepared assuming that we will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the … |
| BTIG-LLC | BTIG-LLC | 62% | igations thereunder, we paid $38.0 million in cash and issued 5,725,190 shares of our Common Stock to the Purchasers. On February 29, 2024, we entered into an underwriting agreement with TD Cowen and… |
| COMPANY-LLC | COMPANY-LLC | 62% | igations thereunder, we paid $38.0 million in cash and issued 5,725,190 shares of our Common Stock to the Purchasers. On February 29, 2024, we entered into an underwriting agreement with TD Cowen and… |
| OBERLAND-CAPITAL-MANAGEMENT-LLC | OBERLAND-CAPITAL-MANAGEMENT-LLC | 62% | e liability: Loan Agreement Conversion Derivative Liability ($ in thousands) Three Months Ended March 31, 2026 Fair value as of beginning of period $ ( 850 ) Change in fair value included in other in… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HUMA-DEBT-10115 | Warrants outstanding: 32961 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| HUMA-DEBT | Debt stack $66.5M | 90% | Market cache reports total debt of $66.5M. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc. | 100.00 | 1 | ['supplier'] |
| FMS | Fresenius Medical Care AG | 100.00 | 1 | ['supplier'] |
| CTSO | Cytosorbents Corporation | 50.00 | 2 | |
| BAX | Baxter International Inc. | 50.00 | 2 | |
| BDX | Becton, Dickinson and Company | 50.00 | 2 | |
| DNABW | Ginkgo Bioworks Holdings, Inc. | 50.00 | 2 | |
| EHC | Encompass Health Corporation | 50.00 | 2 | |
| DNA | Ginkgo Bioworks Holdings, Inc. | 50.00 | 2 | |
| FSNUY | Fresenius SE & Co. KGaA | 50.00 | 2 | |
| RGEN | Repligen Corporation | 50.00 | 2 | |
| BHPLF | BHP Group Limited | 50.00 | 2 | |
| CLLS | Cellectis S.A. | 50.00 | 2 | |
| FMCQF | Fresenius Medical Care AG | 50.00 | 2 | |
| ICLR | ICON Public Limited Company | 50.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| HUMAW | Humacyte, Inc. | 50.00 | 2 | |
| IDXG | Interpace Biosciences, Inc. | 50.00 | 2 | |
| GH | Guardant Health, Inc. | 50.00 | 2 | |
| CLWT | Euro Tech Holdings Company Limited | 50.00 | 2 |